Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients

Drug and Alcohol Dependence

Volumn 118, Issue 2-3, 2011, Pages 326-334

  McCance Katz, Elinore F ^a   Moody, David E ^b   Prathikanti, Sudha ^a   Friedland, Gerald ^c   Rainey, Petrie M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Buprenorphine naloxone; Drug interactions; Opioid addiction; Rifabutin; Rifampin; Tuberculosis

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; RIFABUTIN; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; AROUSAL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG METABOLISM; FEMALE; HUMAN; MALE; OPIATE ADDICTION; PR INTERVAL; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; WITHDRAWAL SYNDROME;

ADULT; ANTITUBERCULAR AGENTS; BUPRENORPHINE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RIFABUTIN; RIFAMPIN; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 80053564702     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.04.013     Document Type: Article

References (43)

1. Altice F.L., Kamarulzaman A., Soriano V.V., Schechter M., Friedland G.H. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010, 376:367-387.
2. Benedetti M.S. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol. Res. 1995, 32:177-187.
3. Brogden R.N., Fitton A. Rifabutin: a review of its antimicrobial activity, pharmacokinentic properties and therapeutic efficacy. Drugs 1994, 47:983-1009.
4. Brown L.S., Sawyer R.C., Li R., Cobb M.N., Colborn D.C., Narang P.K. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Depend. 1996, 43:71-77.
5. Burman W., Gallican K., Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 2001, 40:327-341.
6. Centers for Disease Control and Prevention Prevention and treatment of tuberculosis among patients with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm. Rep. 1998, 47:11-15.
7. Centers for Disease Control and Prevention Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Recomm. Rep. 2000, 49:185-189.
8. Chang Y., Fang W.B., Lin S.N., Moody D.E. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin. Pharmacol. Toxicol. 2010, 10.1111/j.1742-7843.2010.00628.x.
9. Chang Y., Moody D.E., McCance-Katz E.F. Novel metabolites of buprenorphine in human liver microsomes and human urine. Drug Metab. Dispos. 2006, 34:440-448.
10. Chang Y., Moody D.E. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab. Lett. 2009, 3:101-107.
11. Cone E., Gorodetzky C., Yousefnejad D., Buchwald W., Johnson R. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 1984, 12:577-581.
12. Conover C., Rizdon R., Valway S., Schoenstadt L., McAuley J., Onorato I., Paul W. Outbreak of multi-drug resistant tuberculosis at a methadone treatment program. Int. J. Tuberc. Lung Dis. 2001, 5:59-64.
13. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
14. Friedland G. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J. Acquir. Immune Defic. Syndr. 2010, 55:S37-S42.
15. Gallicano K.D., Sahai J., Shukla V.K., Seguin I., Paluts A., Kwok D., Foster B.C., Cameron D.W. Induction of zidovudine glucuronidation and amidation pathways by rifampicin in HIV-infected patients. Br. J. Pharmacol. 1999, 48:168-179.
16. Hassan H.E., Myers A.L., Coop A., Eddington N.D. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J. Pharm. Sci. 2009, 98:4928-4940.
17. Huang W., Moody D.E., McCance-Katz E.F. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther. Drug Monit. 2006, 28:245-251.
18. Iribarne C., Berthou F., Baird S., Dréano Y., Picart D., Bail J.P., Beaune P., Ménez J.F. Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 1996, 9:365-373.
19. Iribarne C., Picart D., Dreano Y., Bail J.P., Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997, 60:1953-1964.
20. Kreek M.J., Garfield J.W., Gutjahr C.L., Giusti L.M. Rifampin-induced methadone withdrawal. N. Engl. J. Med. 1976, 294:1104-1106.
21. Kuhlman J.J., Levine B., Johnson R.E., Fudala P.J., Cone E.J. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998, 93:549-559.
22. Loos U., Musch E., Jensen J.C., Mikus G., Schwabe H.K., Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochemschr. 1985, 163:1205-1211.
23. McCance-Katz E.F., Moody D.E., Morse G.D., Friedland G., Pade P., Baker J., Alvanzo A., Smith P., Ogundele A., Jatlow P., Rainey P.M. Interactions between buprenorphine and antiretrovirals I: nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin. Infect. Dis. 2006, 43:S224-S234.
24. McCance-Katz E.F., Moody D.E., Morse G.D., Ma Q., DiFrancesco R., Friedland G., Pade P., Rainey P.M. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007, 91:269-278.
25. McCance-Katz E.F., Rainey P., Friedland G., Jatlow P. The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. 2003, 37:476-482.
26. McCance-Katz E.F., Rainey P.M., Moody D.E. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am. J. Addict. 2010, 19:38-46.
27. McCance-Katz E.F., Sullivan L.S., Nallani S. Drug interactions of clinical importance between the opioids, methadone and buprenorphine, and frequently prescribed medications: a review. Am. J. Addict. 2010, 19:4-16.
28. McCance-Katz E.F. Office based treatment of opioid dependence with buprenorphine. Harv. Rev. Psychiatry. 2004, 12:321-338.
29. McCance-Katz E.F. Treatment of opioid dependence and HIV/HCV co-infection in opioid dependent patients: the importance of drug interactions between opioids and antiretroviral medications. Clin. Inf. Dis. 2005, 41:S89-S95.
30. Moody D.E., Chang Y., Huang W., McCance-Katz E.F. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin. Pharmacol. Toxicol. 2009, 105:211-215.
31. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., Foltz R.L. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 2002, 306:31-39.
32. Nieimi M., Backman J.T., Fromm M.F., Neuvonen P.J., Kivisto K.T. Pharmacokinetic interactions with rifampicin. Clin. Pharmacokinet. 2003, 42:819-850.
33. Oesch F., Arand M., Benedetti M.S., Castelli M.G., Dostert P. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J. Antimicrob. Chemother. 1996, 37:1111-1119.
34. Paine M.F., Wagner D.A., Hoffmaster K.A., Watkins P.B. Cytochrome P450 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin. Pharmacol. Ther. 2002, 72:524-535.
35. Rich J.D., McKenzie M., Shield D.C., Wolf F.A., Key R.G., Poshkus M., Clarke J. Linkage with methadone treatment upon release from incarceration: a promising opportunity. J. Addict. Dis. 2005, 24:49-59.
36. Sekar V., Lavreys L., Van de Casteele T., Berckmans C., Spinosa-Guzman S., Vangeneugden T., De Pauw M., Hoetelmans R. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob. Agents Chemother. 2010, 54:4440-4445.
37. Shenoi S., Heysell S., Moll T., Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr. Opin. Infect. Dis. 2009, 22:11-17.
38. Skinner M.H., Hsieh M., Torseth J., Pauloin D., Bhatia G., Harkonen S., Merigan T.C., Blaschke T.F. Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother. 1989, 33:1237-1241.
39. Totah R.A., Sheffels P., Roberts T., Whittington D., Thummel K., Kharasch E.D. Role of CYP 2B6 in human methadone metabolism. Anesthesiology 2008, 108:363-374.
40. Wang W., Xiao H., Lu L. Case-control, retrospective study of pulmonary tuberculosis in heroin abusing patients in China. J. Psychoactive Drugs 2006, 38:203-205.
41. Wesson D.R., Ling W. The clinical opiate withdrawal scale (COWS). J. Psychoactive Drugs 2003, 35:253-259.
42. World Health Organization, 2010. Global Tuberculosis Control. WHO Rep. Geneva.
43. World Health Organization, 2008. Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach. WHO Rep. Geneva.